03 — Diagnostics & Quantified Self
Silo Scope
Objective quantification of biological state: optimal vs. standard clinical reference ranges, multi-omic profiling, and continuous physiological monitoring.
- Upward Index: 00 - Biohacking Index
- Mirrored Lab & Sensor Sourcing Hub: 03 - Diagnostics & Quantified Self Sourcing MOC
- Mirrored Literature Hub: 03 - Diagnostics & Quantified Self References MOC
3.1 Bloodwork & Systemic Biomarkers
Moving beyond pathology detection to longevity-optimal reference ranges.
- Cardiometabolic Panel (ApoB, Lp(a), HbA1c, Fasting Insulin) — ApoB (<60 mg/dL target), Lp(a) genetic risk, HOMA-IR, NMR LipoProfile, Triglyceride:HDL ratio, oxidized LDL
- Inflammation & Oxidative Stress (hs-CRP, Homocysteine, GGT) — hs-CRP (<0.5 mg/L), Homocysteine (<7 µmol/L), Uric Acid, GGT, ESR, Fibrinogen, Myeloperoxidase
- Endocrine & Hormone Panel — Total & Free Testosterone, Estradiol (sensitive LC/MS), SHBG, DHEA-S, IGF-1, Morning Cortisol, Prolactin, LH/FSH
- Thyroid Panel — TSH, Free T3, Free T4, Reverse T3, TPO & Thyroglobulin Antibodies
- Hematology, Iron & Nutrient Panel — CBC with differential, Ferritin, Serum Iron, TIBC, Transferrin Saturation, RBC Magnesium, Serum/RBC Zinc & Copper, 25-OH Vitamin D, Active B12 (Holotranscobalamin), Folate, Omega-3 Index
- Hepatic & Renal Function (Cystatin C, eGFR) — Cystatin C (muscle-independent GFR), Creatinine, BUN, AST, ALT, Bilirubin, Albumin
3.2 Genetics, Epigenetics & Multi-Omics
Constitutional genomic variants and dynamic biological age clocks.
- Methylation & Detox SNPs (MTHFR, COMT, GST) — MTHFR (C677T, A1298C), COMT (Val158Met), MTR/MTRR,PEMT, CBS, GSTM1/GSTP1, SOD2
- Lipid & Longevity Variants (APOE, FOXO3) — APOE (), PCSK9, CETP, LP(a), FOXO3, KLOTHO
- Neurotransmitter & Circadian Variants — BDNF (Val66Met), DRD2, SLC6A4, ADORA2A (caffeine sensitivity), CYP1A2, PER2/CLOCK
- Epigenetic Clocks (DunedinPACE, Horvath, GrimAge) — DNA methylation pace of aging (DunedinPACE < 0.85), GrimAge2, OMICmAge, extrinsic vs. intrinsic age
- Telomere & Biological Age Testing — Leukocyte telomere length, GlycanAge (IgG glycosylation inflammation index)
3.3 Gut Microbiome & GI Diagnostics
Enteric ecology, barrier integrity, and microbial metabolites.
- Microbiome Diversity & Keystone Species — Shotgun metagenomics (16S vs. WGS), Akkermansia muciniphila, Faecalibacterium prausnitzii, Bifidobacterium, Firmicutes/Bacteroidetes
- Intestinal Permeability & Zonulin — Zonulin, LPS (endotoxemia), secretory IgA (sIgA), calprotectin, lactoferrin
- SCFAs (Butyrate, Propionate, Acetate) — Colonocyte fuel, HDAC inhibition, Treg induction, GLP-1 stimulation
- SIBO, Dysbiosis & Organic Acids Test (OAT) — Lactulose/glucose breath testing (, , ), fungal/clostridia metabolites, beta-glucuronidase
3.4 Wearables & Continuous Biometrics
High-frequency longitudinal data capture.
- Continuous Glucose Monitoring (CGM) & Glycemic Variability — Time in tight range (70–110 mg/dL), standard deviation (<15 mg/dL), MAGE, postprandial AUC
- HRV, RHR & Autonomic Readiness — Nocturnal RMSSD vs. morning orthostatic readings, 7-day rolling baseline CV
- Sleep Staging & Actigraphy — Oura / Whoop / Eight Sleep / EEG headbands, sleep efficiency, latency, temperature deviation
- Body Composition (DEXA, Visceral Fat) — Appendicular Lean Mass Index (ALMI), Visceral Adipose Tissue (VAT < 100g), T-score bone density
- Blood Pressure & Pulse Wave Velocity — 24h ambulatory blood pressure monitoring (ABPM), nocturnal dipping, arterial stiffness
Tracked Biomarkers in Vault
| Biomarker Panel | Category | Longevity Optimal | Standard Range | Cadence |
|---|---|---|---|---|
| Blood Pressure & Pulse Wave Velocity | Wearables & Continuous Biometrics | 24h ABPM < 115/75 mmHg · Nocturnal Dipping 10–20% · cfPWV < 6.5 m/s · Central Pulse Pressure < 35 mmHg | Office BP < 120/80 mmHg (Stage 1 HTN >= 130/80) · cfPWV < 10.0 m/s · Pulse Pressure < 50 mmHg | Weekly Home Morning/Evening Oscillometric Cuff + Annual 24h ABPM & PWV Assessment |
| Body Composition (DEXA, Visceral Fat) | Wearables & Continuous Biometrics | VAT Mass < 100–250 g (Area < 50 cm2) · ALMI > 9.0 kg/m2 (M) / > 7.0 kg/m2 (F) · BMD Z-Score > +1.0 | VAT Area < 100 cm2 (< 500 g) · ALMI > 7.0 kg/m2 (M) / > 5.5 kg/m2 (F) · BMD T-Score > -1.0 | Biannual to Annual (standardized fasted morning DEXA scan on identical machine) |
| Cardiometabolic Panel (ApoB, Lp(a), HbA1c, Fasting Insulin) | Bloodwork & Systemic Biomarkers | ApoB < 60 mg/dL · Lp(a) < 30 nmol/L · HbA1c 4.6–5.1% · Fasting Insulin 2.0–5.0 uIU/mL | ApoB < 100 mg/dL · Lp(a) < 75 nmol/L · HbA1c < 5.7% · Fasting Insulin 2.6–24.9 uIU/mL | Quarterly to Biannual (Lp(a) once per lifetime unless on targeted therapy) |
| Continuous Glucose Monitoring (CGM) & Glycemic Variability | Wearables & Continuous Biometrics | 24h Mean 78–92 mg/dL · TITR (70–110) > 90% · SD < 14 mg/dL · CV < 16% · Postprandial Peak < 120 mg/dL | TIR (70–180 mg/dL) > 70% · CV < 36% · Fasting < 100 mg/dL · 2h Postprandial < 140 mg/dL | 14-Day Continuous Sensor Wear Quarterly (or during nutrition/compound titration) |
| Endocrine & Hormone Panel | Bloodwork & Systemic Biomarkers | Free T 15–25 pg/mL (M) / 1.5–3.0 pg/mL (F) · Estradiol 20–35 pg/mL (M) · IGF-1 110–160 ng/mL | Total T 264–916 ng/dL (M) · Estradiol 10–42 pg/mL (M) · IGF-1 55–240 ng/mL | Quarterly to Biannual (drawn 07:30–09:00 AM fasted; luteal Day 19–21 for cycling females) |
| Epigenetic Clocks (DunedinPACE, Horvath, GrimAge) | Genetics, Epigenetics & Multi-Omics | DunedinPACE < 0.80 (ideal 0.65–0.78) · GrimAge2 Accel < -3.0 yrs · PhenoAge Accel < -4.0 yrs | DunedinPACE 1.00 yr/yr · GrimAge2 & Horvath Age Acceleration = 0.0 yrs | Biannual to Annual (avoid testing within 4 weeks of acute viral infection) |
| HRV, RHR & Autonomic Readiness | Wearables & Continuous Biometrics | Nocturnal RMSSD > 60–100+ ms (age-indexed) · 7d lnRMSSD CV 2–6% · RHR 42–54 bpm · HRR1 > 30 bpm | RMSSD 19–75 ms · RHR 60–100 bpm · 1-Min Heart Rate Recovery (HRR1) > 12–18 bpm | Continuous Nocturnal PPG / Morning 5-Min Orthostatic ECG Chest Strap |
| Hematology, Iron & Nutrient Panel | Bloodwork & Systemic Biomarkers | Ferritin 50–100 ng/mL · 25-OH Vit D 45–65 ng/mL · Omega-3 Index 8–12% · RBC Mg 5.5–6.5 mg/dL | Ferritin 15–400 ng/mL · 25-OH Vit D 30–100 ng/mL · Omega-3 Index > 4% · Serum Mg 1.7–2.2 mg/dL | Biannual |
| Hepatic & Renal Function (Cystatin C, eGFR) | Bloodwork & Systemic Biomarkers | Cystatin C 0.60–0.85 mg/L · eGFRcys > 100 mL/min · ALT & AST < 22 U/L · Albumin 4.5–5.2 g/dL | Cystatin C 0.53–1.02 mg/L · eGFR > 60 mL/min · ALT & AST < 40 U/L · Albumin 3.5–5.5 g/dL | Quarterly to Biannual |
| Inflammation & Oxidative Stress (hs-CRP, Homocysteine, GGT) | Bloodwork & Systemic Biomarkers | hs-CRP < 0.5 mg/L · Homocysteine 5.0–7.0 umol/L · GGT < 18 U/L · Uric Acid 3.5–5.0 mg/dL | hs-CRP < 3.0 mg/L · Homocysteine < 15.0 umol/L · GGT < 60 U/L · Uric Acid 3.5–7.2 mg/dL | Quarterly to Biannual |
| Intestinal Permeability & Zonulin | Gut Microbiome & GI Diagnostics | Fecal Calprotectin < 25 ug/g · Fecal Zonulin < 60 ng/mL · sIgA 800–2000 ug/g · LBP < 10 ug/mL | Fecal Calprotectin < 50 ug/g · Fecal Zonulin < 107 ng/mL · sIgA 510–2040 ug/g · Lactoferrin < 7.25 ug/g | Biannual or during inflammatory / autoimmune flare investigation |
| Lipid & Longevity Variants (APOE, FOXO3) | Genetics, Epigenetics & Multi-Omics | FOXO3 rs2802292 G-allele · APOE e2/e3 or e3/e3 · PCSK9 LOF · Phenotypic ApoB < 55 mg/dL (if e4+) | APOE e3/e3 (~60–65% population) · e3/e4 (~20–25%) · e4/e4 (~1–2%) | Once per lifetime (genotyping) + Quarterly lipid/glycemic telemetry for APOE4 carriers |
| Methylation & Detox SNPs (MTHFR, COMT, GST) | Genetics, Epigenetics & Multi-Omics | Phenotypic compensation: Homocysteine 5–7 umol/L · SAM:SAH Ratio > 4.0 · Whole-Blood GSH > 900 umol/L | Wild-type vs. Heterozygous / Homozygous Allelic Call (rs1801133, rs4680, rs7946, GSTM1) | Once per lifetime (WGS/SNP array) + Biannual phenotypic methylation bloodwork |
| Microbiome Diversity & Keystone Species | Gut Microbiome & GI Diagnostics | Shannon Index > 3.5 · F. prausnitzii 8–15% · A. muciniphila 1.5–4.0% · Bifidobacterium 2–8% | Shannon Index > 2.5 · F. prausnitzii 5–15% · A. muciniphila 0.5–5.0% · Pathobionts < 0.1% | Biannual to Annual (Shotgun Metagenomic Sequencing) |
| Neurotransmitter & Circadian Variants | Genetics, Epigenetics & Multi-Omics | Genotype-personalized caffeine cutoff (08:00–12:00 PM) · DLMO alignment · High BDNF expression | CYP1A2*1A/*1F · ADORA2A rs5751876 · BDNF rs6265 · PER2/CLOCK/CRY1 chronotype calls | Once per lifetime (WGS/SNP array) + Continuous actigraphy / HRV validation |
| SCFAs (Butyrate, Propionate, Acetate) | Gut Microbiome & GI Diagnostics | Total SCFAs > 80 umol/g · Molar Ratio 60:20:20 · n-Butyrate > 18 umol/g (20–25% of total) | Total SCFAs 40–100 umol/g · Acetate 50–70% · Propionate 15–25% · Butyrate 10–20% | Biannual (via GC-MS / LC-MS fecal metabolomics + WGS butyryl-CoA gene capacity) |
| SIBO, Dysbiosis & Organic Acids Test (OAT) | Gut Microbiome & GI Diagnostics | 90-min H2 Rise < 20 ppm · CH4 < 10 ppm · H2S < 3.0 ppm · Arabinose < 20 · Beta-Glucuronidase < 1500 U/g | 3-Gas Breath Test Negative · Urinary OAT Fungal & Clostridia Metabolites within 95% Reference Interval | Diagnostic on GI/neuro-fatigue symptom presentation + Post-eradication retest at 4 weeks |
| Sleep Staging & Actigraphy | Wearables & Continuous Biometrics | TST 7.2–8.2 h · Sleep Efficiency > 90% · SWS (N3) 18–25% (1.3–2.0 h) · REM 20–25% (1.5–2.0 h) · SRI > 85 | TST 7.0–9.0 h · Sleep Efficiency > 85% · SWS 13–23% · REM 20–25% · Sleep Latency 10–20 min | Continuous Nightly Wearable Actigraphy/PPG + Periodic Forehead EEG Cross-Validation |
| Telomere & Biological Age Testing | Genetics, Epigenetics & Multi-Omics | GlycanAge < Chronological Age - 5 yrs · Shortest Telomere <20th %ile < 5% · Levine PhenoAge < -5 yrs | Mean LTL 6.5–8.5 kb (age-matched 50th percentile) · GlycanAge = Chronological Age | Annual |
| Thyroid Panel | Bloodwork & Systemic Biomarkers | TSH 0.8–2.0 mIU/L · Free T3 3.2–4.2 pg/mL · Free T4 1.1–1.5 ng/dL · Reverse T3 < 15 ng/dL | TSH 0.45–4.50 mIU/L · Free T3 2.0–4.4 pg/mL · Free T4 0.82–1.77 ng/dL · Reverse T3 9.2–24.1 ng/dL | Biannual (drawn morning fasted; hold biotin supplements 72h prior) |